What is established
- Two ¹⁷⁷Lu radioligand therapies approved and in routine use.
- The theranostic model: image first, treat the patients whose scan shows uptake.
- Reactor supply of ¹⁷⁷Lu and generator supply of ⁶⁸Ga at the imaging site.
Why Radioligand Therapy
A modality that has gone from specialist procedure to mainstream oncology within a decade.
Lutathera was approved in the United States in January 2018 for neuroendocrine tumors, and Pluvicto in March 2022 for prostate cancer. Both are ¹⁷⁷Lu-labeled ligands paired with an imaging agent, and both showed that a theranostic pair can be manufactured and delivered to patients at scale. The targets covered by approved products remain few, and most solid tumors have none. A ligand that binds a new target selectively, with the imaging agent and the manufacturing to go with it, is what the field is short of.
What Aurelius Is Building
Platform
Deep experience across: multiple parallel discovery modalities, including ML and AI, lead and pharmacokinetic optimization via medicinal and radiochemistry, and CMC excellence from first in human carried through to commercial supply. One lead compound generates up to four clinical assets on the same ligand: a ⁶⁸Ga PET agent or cold kit with retained ¹⁸F optionality, and a ¹⁷⁷Lu therapeutic with retained alpha optionality.
Pipeline
Four preclinical theranostic programs against solid-tumor targets with few treatment options, leveraging our unique platform to provide both diagnostic and therapeutic assets. The lead program is in IND-enabling studies, and the clinical read-out of the imaging agent for each program provides an early de-risking of the therapeutic.
Team
A leadership team with deep experience in discovery, optimization, radiochemistry, CMC and clinical supply. A culture of excellence and accountability, driven by a deep conviction and mission to help patients and improve outcomes.
Investor Inquiries
Aurelius does not publish financial information. Materials are available to qualified investors under a confidentiality agreement. Write to info@aureliustherapeutics.com, or use the contact form and select Investment as the subject.
Nothing on this website constitutes an offer to sell or a solicitation of an offer to buy securities of Aurelius Therapeutics B.V. in any jurisdiction. Any offering is made only to qualified investors by private placement under the applicable exemptions, on the basis of separate offering documents.